Learn about COPD medications, including bronchodilators, steroids, and combination treatments. Understand how they work, their side effects, and ways to manage COPD effectively.

Patients with COPD continue to suffer from frequent exacerbations as well as from a high symptom burden despite the optimization of inhaled medications. This study is an example of endotyping whereby ...

In the NOTUS study, the researchers randomized 470 adults with uncontrolled COPD and type 2 inflammation (defined as a blood eosinophil count of ≥ 300 cells/µL) to 300-mg subcutaneous dupilumab ...

Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white ...

However, the drug is not for all COPD patients. It is only approved for people with high levels of eosinophils, a type of immune cell that contributes to inflammation.Regeneron said about 300,000 ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England ...

Individuals with both type 2 diabetes (T2D) and chronic obstructive pulmonary disease (COPD) had higher all-cause and respiratory-cause mortality compared with those without COPD over a 3-year ...

WASHINGTON — At 52 weeks, adults with moderate/severe COPD and type 2 inflammation receiving dupilumab had a lower exacerbation rate and better lung function, according to an American Thoracic ...

Learn about chronic obstructive pulmonary disease (COPD) diagnosis and testing, including spirometry and the electrocardiogram (EKG).

If your doctor suspects you have COPD, you’ll likely undergo a few different tests, including a chest X-ray. Learn how to prepare for an X-ray and what the results could mean. Plus, see pictures ...

Subsequent research, including studies by Regeneron, found that this type of inflammation plays a role in COPD. The EMA approval is based on the results of two Phase 3 clinical trials.

Surya Bhatt, M.D., MSPH Surya Bhatt, M.D., MSPH, professor of medicine in the Division of Pulmonary, Allergy, & Critical Care Medicine, is the latest winner of the Heersink School of Medicine's ...